Ernesto Iacucci

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Adi Diab, Nizar M. Tannir, Salah-Eddine Bentebibel et al. · Cancer Discovery · 2020 · 231 citations · Full text

Unraveling genomic variation from next generation sequencing data

Georgios A. Pavlopoulos, Anastasis Oulas, Ernesto Iacucci et al. · BioData Mining · 2013 · 65 citations · Full text

Which clustering algorithm is better for predicting protein complexes?

Charalampos Moschopoulos, Georgios A. Pavlopoulos, Ernesto Iacucci et al. · BMC Research Notes · 2011 · 28 citations · Full text

Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.

Chantale Bernatchez, Cara Haymaker, Michael E. Hurwitz et al. · Journal of Clinical Oncology · 2017 · 22 citations

Nk Cells 8, T-regulatory Cell, Immunology +27

Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.

Michael E. Hurwitz, Daniel C. Cho, Arjun Vasant Balar et al. · Journal of Clinical Oncology · 2019 · 22 citations

Immunology, Immune Regulation, Pathology +26